Psychedelics vs SSRIs: Why is mental health treatment at a crossroads?

By MDLinx staffFact-checked by Davi ShermanPublished August 12, 2026

Industry Buzz

You can’t dismiss decades of robust clinical data, then promote therapies with limited evidence as the answer. That’s not innovation. That’s inconsistency.

—Ahmad Rehan Khan, MD

For decades, the standard script for depression was pretty straightforward: Assess the patient, recommend psychotherapy when appropriate, prescribe an antidepressant when indicated, and adjust the treatment until something works.

Now, that script is being rewritten. In April, the FDA announced that it was accelerating the development of psychedelic treatments for serious mental illness, including psilocybin for treatment-resistant depression and major depressive disorder and methylone for PTSD.^[]

The agency also cleared an early stage clinical study of noribogaine hydrochloride and said it was advancing guidance intended to support the development of psychedelic medications.^[]

Singling ibogaine out is an interesting choice, given the fact that there’s less research on it than there is on MDMA or psilocybin.

“It really couldn’t have been based solely or even primarily on science, because the science is just so lacking,” Mason Marks, a law professor who specializes in FDA and controlled-substances regulation, told The New Yorker.^[]

At the same time, HHS Secretary Robert F. Kennedy Jr. has been a critic of traditional therapies, such as SSRIs.^[] He’s pushed initiatives aimed at reducing SSRI use, including physician reimbursement for deprescribing support and additional training modules on deprescribing.^[]

Put those stories together, and the contrast is hard to miss. One class of psychiatric drugs is being given a regulatory fast track, while another, with decades of clinical experience behind it, is being publicly questioned.

Ahmad Rehan Khan, MD, a board-certified psychiatrist and addiction medicine physician, summed it up in a post on X: “MAHA narrative: Antidepressants and antipsychotics don’t work and are ‘dangerous.’ Scientific reality: Strong evidence supports their efficacy. Side effects exist, but are well studied and often manageable with proper care. Same voices now pushing psychedelic treatments: Evidence is still emerging, not yet backed by large scale, definitive trials. Risks are real, including psychological harm and misuse potential. You can’t dismiss decades of robust clinical data, then promote therapies with limited evidence as the answer. That’s not innovation. That’s inconsistency.”

So, what’s really going on?

First, let’s be clear: SSRIs aren’t suddenly unsupported

It’s important not to let the political conversation obscure what the research actually shows. SSRIs are not miracle drugs. Plenty of patients don’t respond to them, and some patients experience troublesome adverse effects. But the evidence does not support the idea that SSRIs are broadly ineffective.

For instance, a massive 2018 network meta-analysis published in The Lancet examined 522 randomized trials involving more than 116,000 patients and found that all 21 antidepressants studied were more effective than placebo among adult patients with major depressive disorder.^[]

Effectiveness and tolerability varied substantially between individual drugs, but the overall finding was pretty clear: Antidepressants work, on average, for major depressive disorder.^[]

The issue with SSRIs is the treatment experience

Ask patients why they’re unhappy with their antidepressants and the answer isn’t always “they didn’t work.”

Sometimes it’s:

“I don’t feel like myself.”
“My libido disappeared.”
“I gained weight.”
“I feel emotionally numb.”
“I don’t want to be on medication forever.”

Some of those experiences are well documented. Sexual dysfunction, for example, is a recognized adverse effect of serotonergic antidepressants.^[]

And discontinuation has become an increasingly important part of the conversation. A 2024 systematic review and meta-analysis published in The Lancet Psychiatry found that antidepressant discontinuation symptoms were more common among people stopping antidepressants than among those stopping placebo.^[]

That matters because the public conversation around antidepressants has changed. The question is no longer simply, “Does this medication reduce depressive symptoms?” Patients increasingly ask, “What might happen if I take this medication for 5 years?”

Meanwhile, psychedelics offer a very different story

The pitch for psychedelic therapy is almost tailor-made for a generation increasingly skeptical of conventional psychiatric treatment.

Instead of taking a medication every day for months or years, imagine receiving one or two supervised psychedelic sessions, with intensive psychological support, and potentially experiencing a meaningful reduction in symptoms afterward. The research is intriguing.

In a 2021 New England Journal of Medicine (NEJM) randomized trial, 59 patients with long-standing, moderate-to-severe major depressive disorder were assigned to either psilocybin plus placebo or escitalopram plus two very-low-dose psilocybin administrations. Both groups received psychological support.^[]

At 6 weeks, the primary outcome didn’t show a statistically significant difference between groups. Secondary outcomes generally favored psilocybin, although those analyses were not corrected for multiple comparisons.^[]

The study did not prove that psilocybin was superior to an antidepressant. But it did something potentially more important for the field: It demonstrated that a psychedelic-assisted approach could produce clinically meaningful improvements and justified much larger trials.

Subsequent research has continued to produce promising results, including trials in treatment-resistant depression. A phase 2 study published in NEJM found that a single 25-mg dose of psilocybin produced a greater reduction in depressive symptoms at 3 weeks than a 1-mg control dose, although adverse effects occurred and longer, larger studies were still needed.^[]

So the excitement isn’t coming out of nowhere.

But psychedelics aren’t just ‘better antidepressants’

A psychedelic-assisted therapy session isn’t simply the psychedelic equivalent of swallowing an SSRI. The treatment model is radically different.

A typical psychedelic protocol involves patient selection, preparation, supervised dosing, monitoring during an altered state of consciousness, and some form of psychological support or integration afterward.^[]

That creates a potential advantage: The intervention may engage psychological processes that a conventional daily medication does not.

But it also creates logistical and safety challenges. The patient is deliberately entering an altered state of consciousness.

That raises questions about cardiovascular effects, acute anxiety or panic, psychological destabilization, interactions with other medications, the possibility of precipitating mania or psychosis in susceptible patients, and what happens when treatment moves outside the highly controlled environment of a clinical trial.

Psychedelics may feel more innovative than SSRIs

SSRIs have been around for decades. The public doesn’t experience “30 years of randomized controlled trials” as exciting. It experiences a familiar medication with a long list of possible side effects.

Psychedelics, by contrast, represent novelty. They also offer a compelling narrative: Rather than suppressing symptoms indefinitely, perhaps they can produce a profound psychological experience that helps patients change how they relate to themselves, their trauma, or their circumstances.

In a mental health system where many patients feel they’ve cycled through medications without getting better, the promise of something genuinely different is understandably attractive for patients.

The bottom line

The current policy debate creates a strange juxtaposition. The FDA is explicitly pushing psychedelic drug development forward because existing treatments haven’t adequately addressed serious mental illness, particularly difficult-to-treat conditions.

At the same time, political criticism of SSRIs can sometimes sound as though the existence of treatment failures proves that the medications themselves are fundamentally defective.

Those aren’t the same thing. A treatment can be imperfect without being ineffective. And the fact that a new treatment looks promising doesn't make an older treatment worthless.

We don’t have to choose between “SSRIs are wonderful” and “SSRIs are terrible.” The more scientifically defensible position is considerably less dramatic: SSRIs help many patients, fail others, and cause meaningful adverse effects in some.

Psychedelics may eventually help some of those patients—but the evidence is still developing, and the treatment model brings its own risks and uncertainties.

SHARE THIS ARTICLE